Cavalli Giulio Ricercatore a tempo determinatoMedicinaMED/09 – Medicina Interna

Carriera Scientifica e Incarichi Professionali

2018-oggi: Ricercatore Universitario, (RTDA, SSD MED/09 – Medicina Interna), Facoltà di Medicina e Chirurgia, Università Vita-Salute San Raffaele. Tassonomia molecolare delle malattie infiammatorie, studio dei meccanismi delle risposte infiammatorie e della loro modulazione a scopo terapeutico.

2017-oggi: Medico Consulente, Unità di Immunologia, Reumatologia, Allergologia e Malattie Rare, IRCCS Ospedale San Raffaele, Milano (Italia).

2017: Professore a Contratto, Facoltà di Medicina e Chirurgia, Università Vita-Salute San Raffaele, Milano (Italia). Docente nei corsi di Semeiotica Medica e Terapia Medica.

2017: Assegnista di Ricerca, Facoltà di Medicina e Chirurgia, SSD MED/09, Università Vita-Salute San Raffaele, Milano (Italia). Studio delle basi genetiche delle malattie infiammatorie.

2014-2016: Postdoctoral Researcher, Laboratorio del Prof. Charles A. Dinarello. Studio delle basi genetiche dell’autoimmunità e dei meccanismi naturali di regolazione delle risposte infiammatorie. Department of Medicine, University of Colorado Denver, Aurora, CO (USA)

2016: Specializzazione in Allergologia e Immunologia Clinica con pieni voti assoluti e lode Università Vita-Salute San Raffaele, Milano (Italia)

2011: Laurea in Medicina e Chirurgia con pieni voti assoluti, lode e menzione accademica (Università Vita-Salute San Raffaele, Milano)

2010: Research Intern, Laboratorio del Prof. Salvatore Albani. Studio delle cellule T regolatorie. Translational Immunology, Sanford-Burnham Medical Research Center, La Jolla, CA (USA)

Premi e riconoscimenti

• Primo Premio di Ricerca ‘alla memoria del Prof. Mario Condorelli’, Società Italiana di Medicina Interna, 2018

 

• Mentor for the European Union PATHWAY Project – International career pathways and curriculum for clinician-scientists. 2018

 

• European League Against Rheumatism (EULAR) Course on Health Economics in Rheumatology, Prague (Czech Republic). Selezione Competitiva, 2018

 

• Rare Care Expert Speaker Academy, Berlin (Germany), 2018
• Membro di ‘Emerging EULAR Network (EMEUNET) Working Group’. Selezione competitiva, 2017

 

• Borsa di Studio ‘European League Against Rheumatism (EULAR)’ per International Certificate Program – EUREKA institute for Translational Medicine, 2017

 

• Membro di EUREKA Institute for Translational Medicine. International Certificate Program. Selezione competitiva, 2017

 

• Borsa di Studio ‘Verso EULAR 2017’. Italian Rheumatology Society (SIR), 2016

 

• FDIME Research Award for the Study of Rare Diseases. Foundation for the Development of Internal Medicine in Europe (FDIME), 2016-2017

 

• 12th FDIME/EFIM Seminar on Clinical Research. Foundation for the Development of Internal Medicine in Europe (FDIME) and European Federation of Internal Medicine (EFIM), Paris (France). Selezione competitiva, 2016

 

• European League Against Rheumatism (EULAR) Award, Paris (France), 2014

 

• European League Against Rheumatism (EULAR) Award, Berlin (Germany), 2012

Pubblicazioni Selezionate (2013-2018) / Selected Publications (2013-2018)

 

• De Luca G, Campochiaro C, Dinarello CA, Dagna L, Cavalli G. Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. Ann Intern Med. 2018

 

• Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. Immunol Rev. 2018

 

• Cavalli G, Justice JN, Boyle KE, D’Alessandro A, Eisenmesser EZ, Herrera JJ, Hansen KC, Nemkov T, Stienstra R, Garlanda C, Mantovani A, Dagna L, Seals DR, Joosten LAB, Ballak DB and Dinarello CA. Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration and improves exercise tolerance. Proc Natl Acad Sci U S A. 2017

 

• Cavalli G, Koenders M, Kalabokis V, Kim J, Tan AC, Garlanda C, Mantovani A, Dagna L, Joosten LA, Dinarello CA. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford). 2016

 

• Cavalli G, Pappalardo F, Mangieri A, Dinarello CA, Dagna L, Tresoldi M. Treating Life- Threatening Myocarditis by Blocking Interleukin-1. Crit Care Med. 2016

 

• Cavalli G, Hayashi M, Jin Y, Yorgov D, Santorico SA, Holcomb C, Rastrou M, Erlich H, Tengesdal IW, Dagna L, Neff CP, Palmer BE, Spritz RA, Dinarello CA. MHC class II superenhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. Proc Natl Acad Sci U S A. 2016

 

• Cavalli G, Dinarello CA. Treating rhematological diseases and comorbidities with Interleukin-1 blocking therapies. Rheumatology (Oxford). 2015

 

• Cavalli G, Fallanca F, Dinarello CA, Dagna L. Treating pulmonary silicosis by blocking Interleukin-1. Am J Respir Crit Care Med. 2015

 

• Cavalli G, Biavasco R, Borgiani B, Dagna L. Oncogene-induced senescence as a new mechanism of disease: the paradigm of Erdheim-Chester disease. Front Immunol. 2014

 

• Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel- Wahab O, Heaney ML, Scheel PJ, Feeley NK, Ferrero E, McClain KL, Vaglio A, Colby T, Arnaud L, Haroche J. Consensus Guidelines for the Diagnosis and Clinical Management of Erdheim-Chester Disease. Blood. 2014

 

• Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis. 2013